[Summary] Innovation for Life
Bio-Thera is a global biopharmaceutical enterprise located in Guangzhou, China, grounded in science and innovation. The company is dedicated to developing next-generation innovative drugs and biosimilars for the treatment of tumors, autoimmune diseases, cardiovascular diseases, ophthalmic conditions, and other diseases that threaten human life or health. Committed to becoming a leading enterprise in the global development of antibody drugs, the company has already advanced multiple drugs to market approval. Among them, Betargin® (bevifibatide citrate) has been approved for marketing in China; adalimumab (UK trade name: Qletli®, China trade name: Geleli®) has been approved in China and the UK; tocilizumab (US trade name: TOFIDENCE™, China trade name: Shilirui®) has been approved in China, the US, the EU, Switzerland, and the UK; bevacizumab (trade names: Avzivi® in the US and EU, Pubeixi® in China, Bevyx® in Brazil) has been approved in China, the US, the EU, and Brazil; ustekinumab (US trade name: STARJEMZA™, European trade name: Usymro®) has been approved in the US, EU, and UK. Golimumab (European trade name: Gotenfia®) has been approved in Europe. TOFIDENCE™ has become the first monoclonal antibody drug developed and manufactured by a Chinese pharmaceutical company to receive FDA approval for marketing in the US. The company also has multiple candidate drugs in late-stage clinical trials, with a focus on tumor immunotherapy in the post-PD-1 era and antibody-drug conjugate (ADC) targeted drug development in the oncology field. Bio-Thera always prioritizes patient well-being as its core value, providing safe, effective, and affordable high-quality drugs through innovative research and development to meet urgent unmet therapeutic needs. For more information, please visit the official website or follow our Twitter and WeChat official account.
Bio-Thera Solutions, Ltd., a leading innovative, global biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune diseases, cardiovascular diseases, eye diseases, and other severe unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next-generation antibody discovery and engineering, the company has advanced multiple candidates in late-stage development, including six approved products: QLETLI® (adalimumab) and BETAGRIN® (bevifibatide citrate) Injection in China, STARJEMZA® (ustekinumab) in the US, USYMRO® (ustekinumab) in the EU, Gotenfia® (golimumab) in the EU, TOFIDENCE® (tocilizumab) and AVZIVI® (bevacizumab-tnjn) in the US and EU, a/k/a POBEVCY® in China. In addition, the company has more than 20 promising candidates in clinical trials, focusing on immuno-oncology in the post-PD-1 era and targeted therapies such as antibody-drug conjugates (ADCs). For more information, please visit the official site or follow us on Twitter and WeChat (Bio-Thera).
What does Bio-Thera Solutions, Ltd. require? Who is Bio-Thera Biologics hiring? Bio-Thera Biologics recruitment: 生物/制药/化工/环保类占比最多占38.2%,其次是医疗卫生/美容保健类占32.1%. What education can get in at Bio-Thera Biologics? 本科占比最多占47.8%,其次是大专占18.1%. High education required at Bio-Thera Biologics? 硕士占14.3%,博士占6.8%. Work experience required at Bio-Thera Biologics? 1-3年占比最多占39.6%,其次是不限占32.9%. Where are the job locations at Bio-Thera Biologics? 广州占比最多占67.6%,其次是重庆占3.4%. Based on job postings from the past year, for reference only.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows